GILEAD SCIENCES, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
GILEAD SCIENCES, INC. (GILD) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $20.32 billion as of 2017-12-31, per its 10-K filed 2018-02-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2018-02-27
- 2017-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $20.32B.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $16.27B.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $16.62B.
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $16.74B.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value as first filed |
|---|---|---|
| 2017-12-31 | $20.32B 10-K · filed 2018-02-27 | |
| 2017-09-30 | $16.27B 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $16.62B 10-Q · filed 2017-08-07 | |
| 2017-03-31 | $16.74B 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $17.79B 10-K · filed 2018-02-27 | |
| 2016-09-30 | $6.83B 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $1.59B 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $4.27B 10-Q · filed 2016-05-06 | |
| 2015-12-31 | $11.96B 10-K · filed 2017-02-27 | |
| 2015-09-30 | $3.23B 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $3.28B 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $1.06B 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $1.26B 10-K · filed 2016-02-24 | |
| 2014-09-30 | $875.04M 10-Q · filed 2014-11-05 | |
| 2014-06-30 | $152.75M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $100.64M 10-Q · filed 2014-05-07 | |
| 2013-12-31 | $100.00M 10-K · filed 2015-02-25 | $100.30M 10-K · filed 2014-02-25 |
| 2013-09-30 | $195.44M 10-Q · filed 2013-10-31 | |
| 2013-06-30 | $402.25M 10-Q · filed 2013-08-01 | |
| 2013-03-31 | $95.31M 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $139.44M 10-K · filed 2014-02-25 | |
| 2012-09-30 | $195.51M 10-Q · filed 2012-11-06 | |
| 2012-06-30 | $390.59M 10-Q · filed 2012-08-01 | |
| 2012-03-31 | $48.17M 10-Q · filed 2012-05-04 | |
| 2011-12-31 | $1.32B 10-K · filed 2013-02-27 | |
| 2011-09-30 | $1.24B 10-Q · filed 2011-11-04 | |
| 2011-06-30 | $754.96M 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $1.42B 10-Q · filed 2011-05-09 | |
| 2010-12-31 | $1.53B 10-K · filed 2012-02-23 | |
| 2009-12-31 | $685.75M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |